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A B S T R A C T
Human kinesin centromere-associated protein E (CENP-E), one of spindle checkpoint proteins, has been iden-
tified as a tumor suppressor in several types of cancer, however, its role in hepatocarcinogenesis remains un-
known. Here we investigated the role of CENP-E in human hepatocellular carcinoma (HCC) employing HCC cell
lines (Hep3B, SMMC7721, and QGY7701), animal models, and patient’s clinical samples and data. We de-
monstrated that down-regulation of CENP-E by CENP-E-silencing shRNAs significantly promoted HCC pro-
liferation/growth both in vitro and in vivo. Further studies found that CENP-E suppressed the proliferation of HCC
cells by halting cell cycle progression at the G1-S phase and accelerating cell apoptosis. Analyses of HCC patient
samples and clinical data revealed that CENP-E was significantly down-regulated in HCC tissues and low CENP-E
expression was significantly associated with patient’s adverse clinicopathological features: poor prognosis, ad-
vanced TNM stage, metastasis, and larger tumor size. Multivariate analysis indicated that CENP-E was an in-
dependent prognostic factor predicting outcomes of advanced HCC patients. Our data suggest that loss of CENP-
E contributes to HCC development and is strongly associated with adverse HCC clinical pathology. Thus, CENP-E
could be a novel target for new treatments and a useful prognostic biomarker for HCC patients.
1. Introduction
Hepatocellular carcinoma (HCC) is the fifth most common type of
malignancy in humans and ranked second worldwide in cancer mor-
tality; the highest incidence and mortality rates being in Eastern and
South-Eastern Asia [1]. Approximately 782,500 new cases of liver
cancer are estimated each year [2]. The incidence of HCC in China is
the fourth most common cancer with over 492,000 new cases every
year, counting for approximately 55 % of total HCC new cases world-
wide [3]. While the prevalence of many cancer types such as lung
cancer is declining, the incidence of liver cancer is increasing in the
United States, from 2.6–8.6 per 100,000 between 1975 and 2011 [2].
Adding to the burden, HCC is an aggressive cancer with a poor prog-
nosis with an overall ratio of mortality to incidence of 0.95 [1,4]. The
majority of HCC patients are diagnosed at an advanced stage when
treatment options are limited and most available treatments are
ineffective. Therefore there is an urgent need to improve treatment
outcomes by identifying novel therapeutic targets and actionable
prognosis predictors for advanced stage hepatocellular carcinoma [5].
The mitotic kinesin centromere-associated protein E (CENP-E) is a
large (312 kDa) kinesin motor protein localized on the kinetochore; it
accumulates in the late G2 phase of the cell cycle and plays an essential
role during metaphase chromosome alignment and the mitotic check-
point [6–10]. During mitosis, CENP-E serves to link chromosomes and
the microtubules of the mitotic spindle [11–13]. CENP-E also activates
the major cell cycle control mechanism to prevent chromosomal mis-
segregation that can result in aneuploidy [8,9]. Reduction of CENP-E
produces aneuploid progeny leading to chromosomal instability (CIN)
[9,11–14]. CIN is a hallmark in most solid cancers such as hepatocel-
lular carcinoma [15]. As a type of genomic instability, CIN, occurs
frequently in many cancer cells [16,17]. Previous studies demonstrated
that increased aneuploidy by inhibiting CENP-E in aged CENP-E+/−
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mice led to the development of spontaneous spleen and lung tumors
more frequently than the wild-type counterparts [14]. However, in-
hibition of CENP-E has also been reported to initiate tumor cell apop-
tosis or regression [18]. Thus, CENP-E can both suppress and promote
tumors [14,17,19].
As one of spindle checkpoint proteins (SCP), CENP-E has a crucial
role to play in the process of cell division, ensuring faithful chromo-
some segregation. Interruption of the spindle checkpoints has long been
known to be involved in aneuploidy and tumorigenesis [20]. Links
between centromere proteins and solid tumors such as breast cancer,
ovarian cancer and HCC have also been demonstrated [19,21,22]. It is
believed that studies investigating centromere proteins, such as CENP-
E, in cancer tissues could uncover molecular mechanism of carcino-
genesis and lead to novel cancer biomarker discoveries and enhance
prognosis estimation of cancer patients [23].
The importance of CENP-E functioning as a tumor suppressor in
liver cancer is supported by a few studies. It has been shown that there
is a reduction in CENP-E expression in HCC tissue [24]. The authors
further confirmed that CENP-E reduction in a normal liver cell line,
LO2, using shRNA expressing vectors to knock down CENP-E, resulted
in chromosome abnormality, aneuploidy [24]. Liu et al. recently re-
ported that significant lower expression of CENP-E was found in human
hepatoma cells compared to LO2 normal hepatic cells [25]. Despite
these findings, to-date, there is no evidence linking reduced expression
of CENP-E to the initiation and development of HCC. Furthermore, no
study to-date has been conducted to investigate the clinical relevance of
reduced CENP-E in HCC patients.
In this study, we investigated the contribution of reduced expression
of CENP-E protein in promoting HCC and the clinical relevance of re-
duced CENP-E in HCC patients utilizing human liver cancer cell lines
(Hep3B, SMMC7721, and QGY7701), animal models, and human HCC
specimens with clinical data.
2. Materials and methods
2.1. Cell culture
Human liver cancer cell lines Hep3B, SMMC7721 and QGY7701
were purchased from the Typical Culture Preservation Commission cell
bank (Chinese Academy of Sciences, Shanghai, China). The other HCC
cell lines PCL5, Hep G2, and Huh7 were preserved in our laboratory. All
these cells were cultured in DMEM (Hyclone, Logan, Utah, USA) sup-
plemented with 10 % fetal bovine serum (FBS) (Gibco, Invitrogen,
Paisley, UK), and maintained in a 37 °C humidified incubator in the
presence of 5 % CO2. The identity of all cell lines used was confirmed
by relevant authorized STR reports.
2.2. Patients and clinical tissue specimens
A total of 90 pairs of clinical liver cancer samples and matched
adjacent non-tumor tissue samples, presented as tissue microarrays
(TMAs) chips, containing pathological and clinical information were
purchased from Shanghai Outdo Biotech Co. Ltd (Shanghai, China). The
use of these materials for research purpose was approved by the
Taizhou Hospital Human Ethics Committee with relevant patients’
consents. Clinical data were available for all clinical samples, including
age, gender, tumor size, tumor location, liver cirrhosis, metastasis, TNM
stage, differentiation status, and patient survival time.
To validate the results from our clinical samples, a small set of data
on CENP-E expression levels in HCC samples from a published study
[24] was extracted (sTable 1). Independent datasets from Oncomine
Cancer Microarray Database (https://www.concomine.org) containing
data on the expression of CENP-E in HCC samples were used to analyze
CENP-E expression in human HCC samples and its associations with
overall survival. Extracted data were included in Supplementary Tables:
sTable 2 and sTable 3.
2.3. RNA interference and transfection
For down-regulation of human CENP-E (NM_001813), CENP-E-si-
lencing shRNAs were designed, synthesized, and cloned into the
pGPU6/GFP/Neo plasmid vector. The sh-CENP-E gene-targeted se-
quence used was (5′ CACCGCCACTAGAGTTGAAAGATAATCAAGAG
TTATCTTTCAACTCTAGTGGCTTTTTTG), and a scrambled sequence
was used as the sequence control (Shanghai GenePharma Co. Ltd,
Shanghai, China). Lipofectamine 2000™ (Invitrogen, Carlsbad, CA,
USA) was used to transfect the recombinant plasmids into Hep3B,
SMMC7721, and QGY7701 cells. After G418 selection (1mg/ml) for 14
days, pooled G418-resistant stable cells, transfected successfully, were
established. The protein level of CENP-E was determined by Western
blot.
2.4. Immunohistochemistry (IHC) and scoring
IHC and scoring were conducted according to the methods pub-
lished previously [26] with modifications [27]. Briefly, the TMAs were
heated for 3 h at 65 °C, then deparaffinized and rehydrated through
dimethylbenzene and graded alcohols, then briefly rinsed in tap water
(several seconds). Endogenous peroxidase was blocked with 3 % hy-
drogen peroxide for 15min at room temperature. The slides were rinsed
in 0.01mol/L phosphate-buffered saline solution (PBS) for 3min with
three repeat washes. Antigen retrieval was performed in 10mM sodium
citrate, pH 6.0, and placed in a microwave oven for 20min. After
30min of pre-incubation in 10 % normal goat serum, to prevent non-
specific staining, the TMAs were incubated (2 h at room temperature)
with primary antibody; anti-CENP-E in a 1:200 dilution in PBS (Santa
Cruz Biotechnology, Dallas, USA). After washing the slides with PBS,
3×3min, the slides were incubated with horseradish peroxidase
(HRP)-labeled anti-rabbit/mouse secondary antibodies (Gene Tech,
Shanghai, China) for 30min at room temperature. The tissues were
stained with DAB working solution (1:50; Gene Tech, Shanghai, China).
Hematoxylin staining was performed on the TMAs for 5min, then de-
hydrated through a series of graded alcohols. The degree of im-
munostaining of the sections was viewed and scored separately by two
independent pathologists blinded to the histopathological features and
patient data. The intensity of CENP-E staining was scored as negative
(0), weak (1), moderate (2) and strong (3). The extent of CENP-E
staining was defined as the percentage of positive stained cells: 1 (< 10
%), 2 (10–50 %), 3 (51–80 %), and 4 (> 80 %). The level of CENP-E
expression in each sample was expressed as an overall score, ranging
from 0 to 12, which was calculated by multiple the score of intensity
and that of extent of staining [27]. CENP-E expression level was con-
sidered high when the final scores were>8 and low or none when the
final scores were ≤8.
Xenograft tumors were sectioned (3−4 μm per section) for IHC
analysis. Primary antibodies used for xenograft tumor staining were
against CENP-E, ARG-1 (Arginase-1) and GPC-3(Glypican-3) at dilu-
tions of 1:100 in PBS (Affinity Biosciences, OH, USA).
2.5. Western blotting
Protein extractions and Western blotting were performed as de-
scribed previously [28]. Primary antibodies include anti-CENP-E
(1:200). β-tubulin was used as a loading control to normalize the pro-
tein signal. All western blot experiments were repeated in biological
triplicates. Protein bands were quantitated using an Odyssey bands
scanner (S/N ODY-2792 model: 9120). The intensities of the bands
were analyzed using Bandscan Software.
2.6. Cell proliferation assay
Cell proliferation assays were performed using the Cell Counting
Kit-8 (CCK-8) (Dojindo, Kumamoto, Japan) as described previously
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[27]. A total of 5×103 cells (Hep3B, SMMC7721, and QGY7701) were
seeded into 24-well plates and cultured for 3 days. Then 20 μl CCK-8
solution was added. After incubated at 37 °C for 4 h, absorbance at
450 nm was measured using a microplate reader (Bio-Rad). Each group
was plated in three duplicate wells. Each experiment was repeated in
biological triplicates.
2.7. Cell cycle analysis
Approximately 1× 106 cells were trypsinized, washed twice with
PBS, and fixed in ice-cold 70 % ethanol for 1 h. The samples were then
centrifuged to remove the ethanol and incubated with 100 μl RNaseA
(keyGEN BioTECH, Nanjing, China) for 30min at 37 °C. Cellular DNA
was stained with propidium iodide (PI). Cell cycle distributions were
determined using a flow cytometer, BD FACSCalibur system, and data
Fig. 1. CENP-E was down-regulated in HCC and correlated with clinicopathological features.
(A) Immunohistochemical analysis of CENP-E expression levels in 90 pairs of liver cancer samples and adjacent tissues. Representative images of CENP-E staining
intensity: (i) strong staining in adjacent tissue; (ii)-(iv) moderate, weak, and negative staining of CENP-E in cancer tissues. 40× magnifications, scale bar 100 μm. (B)
CENP-E expression level associates with liver cancer staging. (i) Strong in adjacent normal tissue; (ii) moderate in TNM stage II; (iii) weak in TNM stage III; (iv)
negative in TNM stage IV. Upper graphs: 10× magnification, scale bar 400 μm; lower graphs: 40× magnification, scale bar 100 μm. (C) IHC scores of CENP-E protein
expression level in paired liver cancer tissue and adjacent tissue (P < 0.001, Student’s t-test).
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were analyzed using CellQuest software, as descripted previously [27].
2.8. Cell apoptosis assay
Approximately 1×106 cells were harvested and stained with
AnnexinV-APC and PI according to the manufacturer’s protocol
(keyGEN BioTECH). Annexin V-APC/PI binding was analyzed by flow
cytometry using a BD FACSCalibur system, and data were analyzed
using CellQuest software.
2.9. Cell migration assay
Cell migration activity was measured using Boyden transwell
chambers (8-μm pore, Corning star, Cambridge, USA). Cells in serum-
free medium (30× 104 cells/200 μl) were added to the upper chambers
of transwell plates. Then 10 % FBS-containing medium was added to
the lower chambers as a chemoattractant. After incubation for 4.5 h at
37 °C, cells that had migrated and attached to the lower surface of the
membrane were fixed with methanol and stained with 0.1 % crystal
violet. For quantification, cells were counted under a microscope in five
randomly selected fields (original magnification, 200×).
2.10. Wound closure assays
Wound closure assays were performed in 6-well plates (3×105
cells/well). A scratch was made down the center of each well using a
plastic tip (100 μl size). Along the scratch line, the cells were washed
away and replaced with serum-free medium. Three randomly chosen
identical locations were imaged at 0 and 24 h under light microscopy
(200×) for each replicate. Results are expressed as the distance be-
tween the edges of individual wounds at 24 h and compared with the
t= 0 time point.
2.11. Colony forming assays
Cells in logarithmic growth phase were digested with 0.25 % trypsin
and cells were suspended in DMEM containing 10 % FBS. Cell sus-
pensions from each group were diluted to 1000 cells per well (6-well
plates) and cultured at 37 °C in a humidified incubator in the presence
of 5 % CO2 for 2 weeks. When clones became visible to the naked eye,
Then the medium was removed, and 4 % paraformaldehyde was added
to the 6-well plates for 5min to fix the cell clones. The 4 % paraf-
ormaldehyde was washed off then 0.1 % crystal violet staining was
overlayed on the cells for 15min. The plate was rinsed with water to
remove the excess dye and plates dried at room temperature. Numbers
of cell colony were counted for statistical analysis.
2.12. In vivo Xenograft experiments
BALB/c nude mice aged 5–6 weeks old were purchased from the
Experimental Animal Centre of Southern Medical University
(Guangzhou, China) and maintained under standard pathogen-free
conditions. 200× 104 HCC cells CENP-E down-regulating or scramble
controls were injected subcutaneously into the left or right flanks of
nude mice (n=3 per group). Tumors were measured with calipers to
estimate volume from day 7 to day 20 after injection. The mice were
sacrificed 20 days later and xenograft tumors were photographed and
collected for western blotting and IHC analyses. All experimental pro-
cedures were performed according to the regulation of animal usage for
scientific research of Southern Medical University.
2.13. Statistical analysis
All statistical analyses were carried out with SPSS 23.0 software
(IBM Corp., Armonk, NY). Statistical significance was tested by
Student’s t-test or chi-square test as appropriate. All tests were two-
sided. P < 0.05 was considered statistically significant. Analysis of
patient survival was performed using Kaplan–Meier analysis and Cox
regression analysis (SPSS).
3. Results
3.1. Reduced expression of CENP-E in human HCC tissues
Clinical samples from the cohort of 90 HCC patients, 74 males and
16 females with a mean age of 43 years ranging from 28 to 76 years,
were used for this study. CENP-E expression in the tissue samples was
analyzed in 90 pairs of HCC and adjacent non-cancer tissues by im-
munohistochemistry (IHC). As shown in Fig. 1A and B, positive im-
munostaining were mainly located in both nucleus and cytoplasm of the
para-neoplastic cells. We found that CENP-E protein was detected
abundantly in non-malignant tissues adjacent to HCC tissues. Our
quantification results demonstrated that CENP-E was strongly ex-
pressed in adjacent non-malignant tissues, 86/90 (95.6 %) samples of
adjacent tissues had a score of 12 (maximum score). In contrast, the
expression of CENP-E in human HCC tissues was relatively weak, with
47/90 (52.2 %) of HCC samples having a score of ≤8 representing low
CENP-E expression. In 12/90 (13.3 %) HCC samples, CENP-E was not
detectable with a score of 0. Overall, the IHC results clearly showed that
the expression level of CENP-E in human HCC tissues was significantly
lower than in adjacent non-malignant tissues (8.43 ± 0.41 vs
11.76 ± 0.10, P < 0.0001; Fig. 1C).
3.2. Association between CENP-E expression and clinicopathological
features of HCC
The patient cohort was divided into a low CENP-E expression group
(n= 47) and a high CENP-E expression group (n= 43) based on the
results of IHC staining. Correlations between the HCC clin-
icopathological features and CENP-E expression are summarized in
Table 1. Low expression of CENP-E was positively associated with
tumor size (P < 0.05), metastasis (P < 0.05), and TNM stage
(P < 0.05). Lower CENP-E intensity was associated with higher tumor
stage (Fig. 1B). However, CENP-E expression did not appear to be
Table 1




Expression of CENP-E (case, %) P Value
Low High
Age
≥61 25 13 (52.0 %) 12 (48.0 %) 0.979
< 61 65 34 (52.3 %) 31 (47.7 %)
Gender
Male 74 41 (55.4 %) 33 (44.6 %) 0.194
Female 16 6 (37.5 %) 10 (62.5 %)
Tumor Size (cm)
> 5 50 31 (62.0 %) 19 (38.0 %) 0.038*
≤5 40 16 (40.0 %) 24 (60.0 %)
Liver cirrhosis
Yes 17 7 (41.2 %) 10 (58.8 %) 0.311
No 73 40 (54.8 %) 33 (45.2 %)
Metastasis
Negative 83 40 (48.2 %) 43 (51.8 %) 0.013*
Positive 7 7 (100 %) 0 (0 %)
TNM stage
I+ II 52 21 (40.4 %) 31 (59.6 %) 0.009**
III+ IV 38 26 (68.4 %) 12 (31.6 %)
Differentiation
Well/moderate 65 32 (49.2 %) 33 (50.8 %) 0.54
Poor 25 15 (60.0 %) 10 (40.0 %)
* p < 0.05.
** p < 0.01.
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associated with age, gender, liver cirrhosis and differentiation. These
results provided a strong indication that the loss of CENP-E is involved
in the pathogenesis of HCC.
3.3. Correlation between CENP-E expression and patient survival
Kaplan-Meier analysis revealed that HCC patients with low CENP-E
expression had a higher risk of death (HR 2.023, 95 %CI 1.107–3.696;
P < 0.05; Fig. 2A). Furthermore, stratification of patients by TNM
stage and tumor size revealed that low CENP-E expression only corre-
lated with poor prognosis in specific subgroups of HCC patients: TNM
stage= III/IV (P < 0.001) (Fig. 2B), and tumor size> 5 cm
(P < 0.01) (Fig. 2C). Univariate Cox regression analysis demonstrated
that CENP-E expression and other parameters including tumor size,
metastasis, differentiation, and TNM stage were significantly associated
with overall survival of HCC patients. However, age, sex, and liver
cirrhosis had no prognostic significance in this population (Table 2).
Although multivariate analysis showed that CENP-E expression was not
independently prognostic for all HCC patients (Table 2), CENP-E ex-
pression was identified as an independent prognostic factor for patients
with TNM stage III+ IV (HR: 7.092, 95 %CI: 2.080–24.186, P < 0.01;
Table 3), and HCC patients with tumor size> 5 cm (HR: 4.042, 95 %CI:
1.588–10.285, P < 0.01; Table 4).
Fig. 2. CENP-E expression is correlated with patient survival with stratification.
(A) Kaplan–Meier analysis of overall survival based on CENP-E expression in 90 patients. HCC patients with low CENP-E expression had a higher risk of death
(P < 0.05). (B) Kaplan-Meier survival analysis comparing the survival time of HCC patients with low or high CENP-E expression at different TNM stages (left:
P > 0.05, right: P < 0.001) and tumor sizes (left: P > 0.05, right: P < 0.01).
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3.4. Validation of findings from clinical samples and clinical data
Data on the expression of CENP-E in HCC samples and its clinical
relevance are very limited. We were unable to find an identical cohort
to validate our findings. However, there was one dataset (Lizuka Liver
2, n=60) from Oncomine reporting that the CENP-E mRNA expression
in HCC samples was reduced with a similar trend to the CENP-E protein
level we observed in our clinical samples. In a published study [24], it
was also found that both mRNA and protein expression levels of CENP-
E were significantly reduced in HCC tissues (n=21) compared to the
adjacent tissues (n= 8). These two sets of data provided additional
evidence to support our observation that CENP-E expression was re-
duced in human HCC tissues. As shown in Fig. 2B, Kaplan–Meier ana-
lysis of overall survival of two sets of Oncomine data (n= 99) with
both CENP-E expression and survival revealed that low expression of
CENP-E, as measured by CENP-E DNA copy number, was associated
with poor survival (P=0.01), which is entirely consistent with our
findings.
3.5. CENP-E suppresses HCC cell proliferation in vitro
Different expression of CENP-E was observed in the six HCC cell
lines used in this study (Fig. 3A). Cell lines with minimum CENP-E
expression were avoided for CENP-E knockdown experiments. There-
fore, Hep3B, SMMC7721, and QGY7701 cell lines were chosen for the
study. We further investigated the biological function of CENP-E by
down-regulating the expression of CENP-E in Hep3B, SMMC7721, and
QGY7701 cells. CENP-E knockdown was accomplished by transfecting
cells with recombinant interfering plasmid (pGPU6-GFP-Neo /sh-CENP-
E) to establish stable cell lines. Down-regulation of CENP-E protein in
Hep3B, SMMC7721, and QGY7701 cells was confirmed by western blot
analysis. As shown in Fig. 3A, CENP-E protein level in sh-CENP-E cells
was reduced by approximately one-fold compared with the scramble
control in HCC cells. The effect of CENP-E on cell proliferation in vitro
was assessed using the CCK-8 assay and demonstrated that reduction of
CENP-E significantly increased the proliferation of Hep3B, SMMC7721,
and QGY7701 cells (P < 0.005; Fig. 3B). In addition, the colony for-
mation capability of CENP-E low-expression HCC cell lines was sig-
nificantly enhanced (P < 0.001; Fig. 3C). Cell cycle analysis, by flow
cytometry, showed that CENP-E low-expressing cell lines exhibited a
significant decrease in the percentage of cells in the G1/G0 peak
(P < 0.01), and a concomitant increase in the S phase compared with
the control lines (P < 0.01) (Fig. 3D). The Hep3B, SMMC7721, and
QGY7701 cells with CENP-E knockdown showed decreased apoptosis
compared to the control transfected cell lines (P < 0.05; Fig. 3E).
These results supported that loss of CENP-E expression increased cell
cycle proliferation, increasing cycle transition from G1-S phase and
reduced apoptosis in HCC cells.
3.6. CENP-E suppresses HCC cell migration and invasion in vitro
Boyden chamber migration assays showed that down-regulation of
CENP-E promoted the migration of Hep3B, SMMC7721 and QGY7701
cells toward the bottom chamber (P < 0.001; Fig. 4 A). Consistent with
the Boyden chamber results, monolayer wound healing assays exhibited
similar phenomena, the loss of CENP-E increased the migratory po-
tential of the cells (P < 0.05) (Fig. 4B). These results demonstrated
down-regulation of CENP-E enhanced migration and wound healing.
3.7. CENP-E suppresses tumor growth in vivo
To investigate whether CENP-E affects tumor growth in vivo, HCC
cells were subcutaneously implanted into BALB/c nude mice after
modulation of CENP-E expression in the tumor cells. Twenty days later,
the animals were sacrificed and the tumors were harvested. Down-
Table 2
Univariate and multivariate analysis of potential prognostic factors in HCC patients (HR: hazard ratio and CI confidence interval).
Factors Case No Univariate analysis Multivariate analysis
HR (95 %C I) P value HR (95 %CI) P value
Age (≥61/<61) 25/65 0.908 (0.46–1.794) 0.782
Gender (male/female) 74/16 2.253(0.885–5.737) 0.089
Tumor size (> 5/≤5 cm) 50/40 2.211(1.175–4.161) 0.014*
Liver cirrhosis (negative/positive) 73/17 0.615(0.259–1.459) 0.270
Metastasis(negative/positive) 83/7 0.205(0.089-0.470) 0.000** 0.338(0.140-0.811) 0.015*
TNM stage (I+ II/III+ IV) 52/38 0.345(0.189-0.628) 0.001** 0.412(0.217-0.780) 0.007**
Differentiation (well or moderate/poor) 65/25 0.488(0.267-0.893) 0.020*
CENP-E expression (low /high) 47/43 2.023(1.107–3.696) 0.022* 0.115
* p < 0.05.
** p < 0.01.
Table 3
Multivariate analysis of potential prognostic factors in HCC patients in TNM
stage III/IV (n=38) (HR: hazard ratio and CI confidence interval).
Factors Case No Multivariate analysis
HR (95 %CI) P value
Age (≥61/<61) 29/9 0.918
Gender (male/female) 32/6 7.563 (1.014–56.429) 0.048
Tumor size (> 5/≤5 cm) 35/3 0.288
Liver cirrhosis (negative/positive) 34/4 0.742
Metastasis (negative/positive) 31/7 0.056
Differentiation (well or moderate/
poor)
23/15 0.621
CENP-E expression (low /high) 26/12 7.092(2.080–24.186) 0.002**
** p < 0.01.
Table 4
Multivariate analysis of potential prognostic factors in HCC patients in Tumor
size>5 cm (n= 50) (HR: hazard ratio and CI confidence interval).
Factors Case No Multivariate analysis
HR (95 %CI) P value
Age (≥61/<61) 8/42 0.822
Gender (male/female) 41/9 3.649
(1.089–12.228)
0.036*
TNM Stage (I+ II/III+ IV) 15/35 0.352 (0.135-0.916) 0.032*
Liver cirrhosis (negative/positive) 41/9 0.604
Metastasis (negative/positive) 44/6 0.057
Differentiation (well or moderate/
poor)
33/17 0.476
CENPE expression (low /high) 31/19 4.042
(1.588–10.285)
0.003**
* p < 0.05.
** p < 0.01.
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Fig. 3. Down-regulation of CENP-E expression increased HCC proliferation and colony formation in vitro.
(A) Western blot analysis of CENP-E in six HCC cell lines. Down-regulation of CENP-E expression in Hep3B, SMMC7721, and QGY7701 cells was confirmed by
western blotting. (sh-CENP-E as the gene-targeted silencing sequence, scramble as the irrelevant sequence control). (B) Down-regulation of CENP-E increased HCC
cell proliferation in vitro (P < 0.005). (C) Down-regulation of CENP-E expression increased the colony formation capacity of Hep3B, SMMC7721, and QGY7701 cells
(P < 0.001). (D) Flow-cytometry analysis of the cell cycle progression showed a decrease in the percentage of cells in G0/G1 phase(P < 0.01), and increase in the S
phase of CENP-E-low-expressing HCC cells compared to that of control Hep3B, SMMC7721, and QGY7701 cell lines (P < 0.01). (E)Down-regulation of CENP-E
decreased apoptosis in HCC cells (P < 0.05). Student’s t-test was performed to calculate statistical significance.
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regulation of CENP-E in SMMC7721 cells significantly promoted tumor
growth; the size of CENP-E knockdown SMMC7721 tumors was> 2-
fold greater than that of the control SMMC7721 cells (P < 0.05;
Fig. 5A). Western blotting analysis of tumor tissues confirmed the
down-regulation of CENP-E in tumor cells (Fig. 5B). These results
strongly suggest that CENP-E functions as a tumor suppressor to inhibit
HCC growth in vivo. IHC ARG-1 staining demonstrated no difference in
expression between tumors and controls (P > 0.05), but GPC-3 ex-
pression was significantly higher in CENP-E-low-expressing tumors
versus control tumors (P < 0.05) (Fig. 5C).
4. Discussion
In this study, we demonstrated that down regulation of CENP-E in
HCC cells significantly promoted HCC proliferation/growth in vitro and
in vivo. This is the first piece of evidence connecting reduced expression
of CENP-E with the pathogenesis of HCC, strongly suggesting that
CENP-E is a HCC suppressor, which plays a role in hepatocarcinogen-
esis. Our analysis of 90 HCC clinical samples revealed a strong asso-
ciation between low CENP-E expression in HCC tissues and adverse
clinicopathological features of HCC, in particular, poor prognosis, ad-
vanced TNM stage (stage III/IV), metastasis and larger tumor size
(> 5 cm). Furthermore, we also found, in multivariate analysis, that
CENP-E is an independent prognostic factor predicting disease outcome
of advanced HCC patients. These results support that loss of CENP-E
expression in liver tissue contributes to the progression of HCC, making
CENP-E a novel target for new HCC therapy and a useful prognostic
biomarker for HCC patients.
Previous studies have shown that CENP-E can both promote and
suppress tumors depending on the context [14,17,19,29,30]. Weaver
et al. proposed that the rate of chromosome missegregation or CIN,
resulting from CENP-E suppression, determines on whether the effect is
promotive or suppressive. low rates of CIN are tumor promoting, higher
rates of CIN leads to tumor suppression [17,29]. However, our data
from both in vitro and in vivo studies overwhelmingly supported that
CENP-E in HCC cells/tissues functions as a tumor suppressor only. The
two-ways effect of promoting and/or suppressing tumorigenesis by
CENP-E has not been demonstrated in the present study.
In agreement with our data, Liu and colleagues reported that CENP-
E expression, as determined by Western blot and qPCR, was sig-
nificantly downregulated in human HCC as compared with adjacent
non-tumor tissues. CENP-E levels in the human HCC-derived cell line
HepG2 cells was also diminished to about half of that shown in LO2
cells. [24]. In a recent study, low expression of CENP-E in HepG2 cells
was observed when the cells were under stress [25]. These studies
confirmed that the level of CENP-E protein was reduced, not increased,
in the HCC tissues, which suggested that CENP-E may have a suppres-
sive role in some stages of human hepatocarcinogenesis. An in-
dependent set of data (n=60) from Oncomine also confirmed that
CENP-E expression as measured by mRNA level was reduced in human
HCC samples (sTable 2). However, no further study has been conducted
to define the role of CENP-E in the pathogenesis of HCC. In our study,
we demonstrated for the first time that low expression of CENP-E in
HCC tissues was strongly associated with a number of adverse clinical
features. Furthermore, suppression of CENP-E in HCC cells led to sig-
nificant promotion of tumor growth. Collectively, our data strongly
suggested that the CENP-E protein functions as a tumor suppressor in
HCC, and increasing CENP-E in the tumor potentially results in HCC
suppression. Our findings are supported by previous studies that show
aneuploidy drives tumorigenesis to promote tumor progression. An
Fig. 4. Down-regulation of CENP-E expression promoted HCC migration in vitro.
(A) Down-regulation of CENP-E increased the ability of Hep3B, SMMC7721,and QGY7701cells to migrate toward chemoattractant in transwell chamber assays
(P < 0.001, Student’s t-test); (B) Wound healing assays showed a significant increase of HCC migration by down-regulation of CENP-E in all 3 cell lines(P < 0.001
or P < 0.05, Student’s t-test).
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increase in chromosomal aneuploidy, resulting from suppression of
CENP-E, promotes tumors in some contexts [14,17,29,31]. When CENP-
E expression was inhibited, the chromosomes were unable to separate
procedurally, resulting in an increase in aneuploidy and CIN, a hall-
mark of cancer [19]. Specifically, in liver cells, reduced CENP-E ex-
pression has been shown to interfere with the separation of chromo-
some [24]. Consistent results were also obtained from the study by
Putkey and colleagues who demonstrated that selective deletion of
CENP-E led to aberrant mitoses marked by chromosome missegregation
during tissue regeneration, confirming the essential role of CENP-E in
the maintenance of chromosomal stability [12].
In our laboratory studies and in the clinical sample cohort different
levels of CENP-E suppression were recorded. The overall inhibition of
CENP-E expression in the HCC tissues was about 30 % (8.43/11.76,
Fig. 1C) while the suppression of CENP-E in animal xenograft tumors
was nearly 90 % (Fig. 5C). In all experiments, only the tumor-
promoting effects of reduced CENP-E were observed, regardless of how
low the level of CENP-E protein was expressed in the tissues. Therefore
we were unable to observe any tumor-suppression induced by higher
rates of CIN, possibly resulting from significant suppression of CENP-E
in xenograft tumors, as reported in murine models by other researchers
[17,29]. These data suggest that the effects of CENP-E may be cell type
and species specific. The frequency of aneuploidy and polyploidy in
hepatocytes was noted to be variable between species [32].
Deregulation of signaling pathways during the G1 phase of the cell
cycle represents a major driving force in the initiation and development
of cancer [33]. Interestingly, our in vitro studies revealed that down-
regulation of CENP-E significantly decreased the percentage of cells in
G1/G0 phase and increased the percentage of cells in S phase, sug-
gesting that CENP-E regulates the cell cycle transition from G1-S phase
in HCC. We also observed that down-regulation of CENP-E significantly
decreased cell apoptosis, again suggestive of an apoptotic role for
Fig. 5. Down regulation of CENP-E in HCC cells promoted tumor growth of in vivo.
(A) Down-regulation of CENP-E expression in human HCC derived cell line SMMC7721 cells promoted the growth of HCC in vivo (P < 0.05). (B) Tumors of HCC in
vivo were collected for western blotting. (C) Tumor sections were subjected to IHC staining, showing the increased expression of GPC-3 but no difference of ARG-1
expression in CENP-E-low-expressing tumors versus control tumors (ARG-1:P > 0.05, GPC-3:P < 0.05). 40× magnifications, scale bar 100 μm. Statistical sig-
nificance was tested by Student’s t-test.
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CENP-E a major goal for anticancer therapy [34].
A highlight of this study was the finding that down-regulation of
CENP-E in HCC promoted tumor cell proliferation. This observation was
confirmed in the in vitro experiments, and well substantiated by the in
vivo results. In the in vivo animal study, subcutaneous injection of down-
regulated CENP-E expressing HCC cells into nude mice resulted in
significantly larger (> 2 folds) tumor growth compared to the control
mice. The findings from the in vitro and in vivo animal studies were
further supported by the results from human HCC clinical samples and
data, where low expression of CENP-E in HCC tissues was associated
with adverse clinical features (including larger tumor size and metas-
tasis) and poor HCC patient survival. Multivariate analysis revealed that
CENP-E could be an independent and useful prognostic biomarker
predicting outcomes for HCC patients in the advanced TNM stage III/IV
or tumor size> 5 cm groups. Interestingly, the expression of CENP-E
correlated well with the expression of GPC-3 (Fig. 5C), a specific clin-
ical diagnostic biomarker for HCC [35], adding support for CENP-E as a
potential prognostic biomarker, another translational implication of
CENP-E.
Our work has provided original evidence to strongly support that
reduced expression of CENP-E protein in HCC cells promotes HCC
growth in vitro and in vivo, highlighting the relevance of CENP-E and its
role in promoting tumorigenesis in the liver. However, whether re-
duced/depleted expression of CENP-E in normal liver cells would in-
itiate and drive the formation of spontaneous HCC in vivo is not known.
Furthermore, it would be interesting to explore if upregulation of
CENP-E in HCC cells does lead to inhibition of tumor growth. Thus,
further work is warranted to elucidate the role of CENP-E in the in-
itiation of HCC and as new therapeutic target.
In conclusion, our data from in vitro studies, in vivo animal models,
and human clinical sample analysis, suggest that CENP-E is a tumor
suppressor and reduced level of CENP-E in HCC contributes to tumor
growth. Mechanistically, reduced expression of CENP-E promotes the
growth of HCC through acceleration of cell cycle transition from the G1
to S phase and lead to suppression of apoptosis in HCC cells. Low ex-
pression of CENP-E in the HCC tissue could serve as an independent
prognostic indicator for the poor outcome of advanced HCC patients.
Overall, our work not only provides important evidence supporting a
tumor-suppressive role for CENP-E in HCC and possible underlying
mechanisms providing important insights into the hepatocarcinogen-
esis, but also suggests CENP-E expression as a potential therapeutic
target and prognostic biomarker for HCC patients.
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